For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 33 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is O  [Clear All Filters]
2020
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.. JCI Insight. 5(3)
Dinh CT, Linn KA, Isidro U, Emanuel EJ, Volpp KG, Bond AM, Caldarella K, Troxel AB, Zhu J, Yang L et al..  2020.  Changes in Outpatient Imaging Utilization and Spending Under a New Population-Based Primary Care Payment Model.. J Am Coll Radiol. 17(1 Pt B):101-109.
Ono JG, Kim BI, Zhao Y, Christos PJ, Tesfaigzi Y, Worgall TS, Worgall S.  2020.  Decreased sphingolipid synthesis in children with 17q21 asthma-risk genotypes.. J Clin Invest. 130(2):921-926.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, Ortiz-Pujols S, Zhou XKathy, Dannenberg AJ, Kumar R et al..  2020.  Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City.. Obesity (Silver Spring).
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank SV et al..  2020.  Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.. J Clin Oncol. 38(13):1389-1397.
Khullar D, Ohn JA, Trusheim M, Bach PB.  2020.  Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.. N Engl J Med. 382(5):473-480.
2019
Navathe AS, Emanuel EJ, Bond A, Linn K, Caldarella K, Troxel A, Zhu J, Yang L, Matloubieh SE, Drye E et al..  2019.  Association Between the Implementation of a Population-Based Primary Care Payment System and Achievement on Quality Measures in Hawaii.. JAMA. 322(1):57-68.
Edwards DJ, Cortes M, Rykman-Peltz A, Chang J, Elder J, Thickbroom G, Mariman JJ, Gerber LM, Oromendia C, Krebs HI et al..  2019.  Clinical improvement with intensive robot-assisted arm training in chronic stroke is unchanged by supplementary tDCS.. Restor Neurol Neurosci. 37(2):167-180.
Burke LG, Khullar D, Zheng J, Frakt AB, E Orav J, Jha AK.  2019.  Comparison of Costs of Care for Medicare Patients Hospitalized in Teaching and Nonteaching Hospitals.. JAMA Netw Open. 2(6):e195229.
Schackman BR, Jeng PJ, Flash MJE, Mejia M, Oksuzyan S, Scott JA, Freedberg KA, Kulkarni SP, Garland WH.  2019.  Cost of an HIV Medical Care Coordination Program in Los Angeles County.. J Acquir Immune Defic Syndr. 81(1):e15-e17.
Armer JM, Ballman KV, McCall L, Ostby PL, Zagar E, Kuerer HM, Hunt KK, Boughey JC.  2019.  Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.. JAMA Surg.
D'Onofrio G, E Edelman J, Hawk KF, Pantalon MV, Chawarski MC, Owens PH, Martel SH, VanVeldhuisen P, Oden N, Murphy SM et al..  2019.  Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).. Implement Sci. 14(1):48.
D'Onofrio G, E Edelman J, Hawk KF, Pantalon MV, Chawarski MC, Owens PH, Martel SH, VanVeldhuisen P, Oden N, Murphy SM et al..  2019.  Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).. Implement Sci. 14(1):48.
D'Onofrio G, E Edelman J, Hawk KF, Pantalon MV, Chawarski MC, Owens PH, Martel SH, VanVeldhuisen P, Oden N, Murphy SM et al..  2019.  Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).. Implement Sci. 14(1):48.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Awad SF, O'Flaherty M, El-Nahas KG, Al-Hamaq AO, Critchley JA, Abu-Raddad LJ.  2019.  Preventing type 2 diabetes mellitus in Qatar by reducing obesity, smoking, and physical inactivity: mathematical modeling analyses.. Popul Health Metr. 17(1):20.